Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
As recently as 10 years ago, the words “machine learning” evoked thoughts of sentient robots and fears of the...
Despite tremendous progress against cancer in the past few decades, not all Americans have benefited equally from advances in...
Seven immune checkpoint inhibitors, targeting the PD-1, PD-L1, or CTLA-4 proteins, are currently approved for the treatment of cancer....
The most recent edition of The Cancer Letter features an op-ed from AACR President David A. Tuveson, MD, PhD,...
The new year brings a new chapter in the holy book of cancer biology with the publication in the...
Each year in the United States, about 14,480 women are diagnosed with cervical cancer, and about 4,290 women die of...
Guest Post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today The size of the known universe is mind-boggling. At times,...
The recently launched Cancer Research Communications (CRC) is the latest addition to the AACR’s journal portfolio. The new journal...
Surrounding a tumor is a vast network of blood vessels, immune cells, proteins, and even bacteria, all of which...
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented...